Associated Papers
CYP2D6 (C2850T, G1846A, C100T) polymorphisms, haplotypes and MDR analysis in predicting coronary artery disease risk in north-west Indian population: A case-control study.
Bhat MA et al.
Gene, 2018
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Lan B et al.
International Journal of Cancer, 2018
CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study.
Wickramage I et al.
Breast Cancer (dove Medical Press), 2017
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.
Goetz MP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM et al.
Journal of the National Cancer Institute, 2012
Select a paper to view details